SOX2 and Bcl-2 as a Novel Prognostic Value in Hepatocellular Carcinoma Progression
Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases en...
Saved in:
| Published in | Current oncology (Toronto) Vol. 28; no. 4; pp. 3015 - 3029 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
MDPI
09.08.2021
MDPI AG |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1718-7729 1198-0052 1718-7729 |
| DOI | 10.3390/curroncol28040264 |
Cover
| Abstract | Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features, tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2 were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators were calculated. Survival rates were determined by Kaplan–Meier survival curves. SOX2 and Bcl-2 were remarkably overexpressed in HCC patients compared to controls (p = 0.04 and p = 0.003, respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with TNM staging (p = 0.02, p = 0.04) and tumor grading (p = 0.01, p = 0.003), respectively. A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate (p = 0.04); however, there was no significant association between Bcl-2 and survival (p = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment. |
|---|---|
| AbstractList | Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features, tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2 were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators were calculated. Survival rates were determined by Kaplan–Meier survival curves. SOX2 and Bcl-2 were remarkably overexpressed in HCC patients compared to controls (p = 0.04 and p = 0.003, respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with TNM staging (p = 0.02, p = 0.04) and tumor grading (p = 0.01, p = 0.003), respectively. A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate (p = 0.04); however, there was no significant association between Bcl-2 and survival (p = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment. Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features, tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2 were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators were calculated. Survival rates were determined by Kaplan-Meier survival curves. SOX2 and Bcl-2 were remarkably overexpressed in HCC patients compared to controls (p = 0.04 and p = 0.003, respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with TNM staging (p = 0.02, p = 0.04) and tumor grading (p = 0.01, p = 0.003), respectively. A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate (p = 0.04); however, there was no significant association between Bcl-2 and survival (p = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment.Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features, tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2 were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators were calculated. Survival rates were determined by Kaplan-Meier survival curves. SOX2 and Bcl-2 were remarkably overexpressed in HCC patients compared to controls (p = 0.04 and p = 0.003, respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with TNM staging (p = 0.02, p = 0.04) and tumor grading (p = 0.01, p = 0.003), respectively. A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate (p = 0.04); however, there was no significant association between Bcl-2 and survival (p = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment. Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features, tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2 were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators were calculated. Survival rates were determined by Kaplan–Meier survival curves. SOX2 and Bcl-2 were remarkably overexpressed in HCC patients compared to controls ( p = 0.04 and p = 0.003, respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with TNM staging ( p = 0.02, p = 0.04) and tumor grading ( p = 0.01, p = 0.003), respectively. A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate ( p = 0.04); however, there was no significant association between Bcl-2 and survival ( p = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment. Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs). In many types of cancer, SOX2 is dysregulated due to overexpression associated with tumor progression and low survival rate. Many HCC cases encounter recurrence and metastasis which might be due to CSCs and also apoptosis. Since little is known about the expression pattern of SOX2 and apoptotic genes in HCC, we aimed to determine the prognostic significance of SOX2, Bax, and Bcl-2 in clinicopathological features, tumor progression, and survival rate of the HCC patients. The expression of SOX2, Bax, and Bcl-2 were evaluated using qRT-PCR in 53 formalin-fixed, paraffin-embedded tissues (FFPE) of patients and 44 controls. Correlation of these genes was analyzed with clinicopathological features and tumor progression. The correlationship between SOX2 expression and ALBI grade as prognostic indicators were calculated. Survival rates were determined by Kaplan-Meier survival curves. SOX2 and Bcl-2 were remarkably overexpressed in HCC patients compared to controls ( = 0.04 and = 0.003, respectively). A significant association was found for both SOX2 and Bcl-2 overexpression with TNM staging ( = 0.02, = 0.04) and tumor grading ( = 0.01, = 0.003), respectively. A significant correlation was observed: patients with SOX2 overexpression had a lower 5-year overall survival rate ( = 0.04); however, there was no significant association between Bcl-2 and survival ( = 0.5). Collectively, overexpression of SOX2 and Bcl-2, alone or combined, may be a potential marker to evaluate prognosis and response to HCC treatment. |
| Author | Tehrani, Mohsen Cucchiarini, Magali Rakhshani, Nasser Babaei, Mohammad Reza Madry, Henning Ajami, Abolghasem Rafiei, Alireza Nikbin, Behrooz Hosseini-khah, Zahra |
| AuthorAffiliation | 3 Department of Interventional Radiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran 15937-47811, Iran; babaei.mr@iums.ac.ir 1 Diabetes Research Center, Mazandaran University of Medical Sciences, Sari 48166-33131, Iran; z.hosseinikhah@mazums.ac.ir 8 Gastrointestinal and Liver Diseases Research Center, Firoozgar Hospital, Iran University of Medical Sciences, Tehran 15937-47811, Iran; Rakhshani.n@iums.ac.ir 4 Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari 48166-33131, Iran; mtehrani@mazums.ac.ir 6 Center of Experimental Orthopedics, Saarland University Medical Center, Kirrbergerstr. Bldg 37, D-66421 Homburg, Germany; magali.madry@uks.eu (M.C.); henning.madry@uks.eu (H.M.) 2 Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Science, Tehran 55469-14177, Iran 7 Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari 48471-91628, Iran 9 Departm |
| AuthorAffiliation_xml | – name: 1 Diabetes Research Center, Mazandaran University of Medical Sciences, Sari 48166-33131, Iran; z.hosseinikhah@mazums.ac.ir – name: 9 Department of Immunology, Tehran University of Medical Sciences, Tehran 14177-55469, Iran – name: 3 Department of Interventional Radiology, Firoozgar Hospital, Iran University of Medical Sciences, Tehran 15937-47811, Iran; babaei.mr@iums.ac.ir – name: 5 Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari 48471-91628, Iran; a.ajami@mazums.ac.ir – name: 4 Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari 48166-33131, Iran; mtehrani@mazums.ac.ir – name: 6 Center of Experimental Orthopedics, Saarland University Medical Center, Kirrbergerstr. Bldg 37, D-66421 Homburg, Germany; magali.madry@uks.eu (M.C.); henning.madry@uks.eu (H.M.) – name: 7 Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari 48471-91628, Iran – name: 8 Gastrointestinal and Liver Diseases Research Center, Firoozgar Hospital, Iran University of Medical Sciences, Tehran 15937-47811, Iran; Rakhshani.n@iums.ac.ir – name: 2 Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Science, Tehran 55469-14177, Iran |
| Author_xml | – sequence: 1 givenname: Zahra surname: Hosseini-khah fullname: Hosseini-khah, Zahra – sequence: 2 givenname: Mohammad Reza surname: Babaei fullname: Babaei, Mohammad Reza – sequence: 3 givenname: Mohsen surname: Tehrani fullname: Tehrani, Mohsen – sequence: 4 givenname: Magali orcidid: 0000-0003-0323-8922 surname: Cucchiarini fullname: Cucchiarini, Magali – sequence: 5 givenname: Henning orcidid: 0000-0002-8612-4842 surname: Madry fullname: Madry, Henning – sequence: 6 givenname: Abolghasem surname: Ajami fullname: Ajami, Abolghasem – sequence: 7 givenname: Nasser surname: Rakhshani fullname: Rakhshani, Nasser – sequence: 8 givenname: Alireza surname: Rafiei fullname: Rafiei, Alireza – sequence: 9 givenname: Behrooz surname: Nikbin fullname: Nikbin, Behrooz |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34436030$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kcluFDEQhi0URBZ4AC7IRy4N3rrdviDBCJJIEUFs4mZVexkceezB7o7E28fJhCgBiZNLVX99VeX_EO2lnBxCzyl5xbkir81SSk4mRzYSQdggHqEDKunYScnU3r14Hx3WekEI51LKJ2ifC8EHwskB-vzl_AfDkCx-Z2LXoooBf8yXLuJPJa9TrnMw-DvExeGQ8InbwpyNi3GJUPAKigkpb-BGXFytIaen6LGHWN2z2_cIffvw_uvqpDs7Pz5dvT3rjBj6uRuMUUROdgA58kl6MlnmPHPKG--l5ZwoJifq2STaHapV2QBcGg_CWkEUP0KnO67NcKG3JWyg_NYZgr5J5LLWUNr20Wk2KkEVd8bZXlCnJiBMtMzo-55Y7hvrzY61XaaNs8aluUB8AH1YSeGnXudLPXLV95Q0wMtbQMm_FldnvQn1-p8gubxUzfpBKDE2L5r0xf1Zd0P-mNIEdCcwJddanL-TUKKvjdf_GN965F89JswwNzvauiH-p_MKCJq1_Q |
| CitedBy_id | crossref_primary_10_1002_iub_2598 crossref_primary_10_1016_j_bbrc_2025_151521 crossref_primary_10_1016_j_semcancer_2022_12_010 crossref_primary_10_3389_fphar_2022_806175 crossref_primary_10_3802_jgo_2024_35_e21 crossref_primary_10_1186_s12957_024_03356_y crossref_primary_10_1007_s00432_024_05756_9 crossref_primary_10_1177_15330338241276895 crossref_primary_10_1016_j_biopha_2023_114336 crossref_primary_10_69601_meandrosmdj_1591577 |
| Cites_doi | 10.1097/00129039-200209000-00004 10.1155/2019/3905817 10.1371/journal.pone.0065380 10.1186/s13058-014-0470-2 10.1038/sj.onc.1209550 10.1371/journal.pone.0071140 10.1002/cncr.10898 10.1158/1055-9965.EPI-14-1228 10.1155/2019/7683817 10.3350/cmh.2012.18.3.258 10.1186/s12885-020-06978-z 10.1371/journal.pone.0008960 10.1002/hep.28690 10.1038/nature13305 10.1097/MD.0000000000015414 10.1007/s00535-014-0951-1 10.1053/j.gastro.2007.04.025 10.1007/s12029-018-00200-x 10.3390/ijms13067663 10.1016/j.cellsig.2013.02.013 10.1007/s12032-013-0503-1 10.1128/JVI.05920-11 10.5306/wjco.v10.i6.234 10.1016/j.semcancer.2019.08.007 10.18632/oncotarget.16570 10.1002/stem.1518 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5 10.1245/s10434-009-0617-z 10.3748/wjg.v8.i6.1059 10.1002/cam4.2968 10.1007/s00292-006-0834-1 10.1038/onc.2012.28 10.1007/BF00690421 10.31557/APJCP.2020.21.10.2961 10.1038/onc.2011.338 10.1074/jbc.M802917200 10.1371/journal.pone.0011022 10.1002/jcb.22050 10.3109/21691401.2015.1105238 10.1155/2020/3761535 10.1111/j.1742-4658.2010.07965.x 10.1186/1471-230X-12-118 10.1186/1471-2407-13-317 10.4067/S0717-95022012000400032 10.1016/S0039-6060(96)80283-2 10.1371/journal.pone.0099594 10.5301/jbm.5000137 10.1038/s41598-018-20086-w 10.1186/s12885-015-2015-1 10.1002/hep.22510 |
| ContentType | Journal Article |
| Copyright | 2021 by the authors. 2021 |
| Copyright_xml | – notice: 2021 by the authors. 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.3390/curroncol28040264 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Open Access Full Text url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1718-7729 |
| EndPage | 3029 |
| ExternalDocumentID | oai_doaj_org_article_2894193eced541e9ba0244198f550d3f PMC8395510 34436030 10_3390_curroncol28040264 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Tehran University of Medical Sciences and Health Services grantid: 27294 – fundername: Iran National Science Foundation grantid: 94001417 – fundername: Mazandaran University of Medical Sciences grantid: 1500 |
| GroupedDBID | --- 04C 29F 2WC 53G 5GY 5VS 6PF AAWTL AAYXX ABDBF ACGFS ACUHS ADBBV AENEX AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BMSDO CITATION CS3 DIK DU5 E3Z EBD EBS EIHBH EJD ESX F5P GROUPED_DOAJ HYE KQ8 MODMG OK1 OVT RNS RPM TR2 TUS CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-6cc907bd6a783b7f0bd2ef2e9fcff7d330927b1f2b41719bd226a37cfa4dd4093 |
| IEDL.DBID | DOA |
| ISSN | 1718-7729 1198-0052 |
| IngestDate | Wed Aug 27 01:32:00 EDT 2025 Thu Aug 21 18:09:26 EDT 2025 Thu Jul 10 23:38:50 EDT 2025 Thu Apr 03 07:07:26 EDT 2025 Tue Jul 01 02:54:37 EDT 2025 Thu Apr 24 22:53:01 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | Bcl-2 Bax cancer stem cell hepatocellular carcinoma SRY-box 2 (SOX2) |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-6cc907bd6a783b7f0bd2ef2e9fcff7d330927b1f2b41719bd226a37cfa4dd4093 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-8612-4842 0000-0003-0323-8922 |
| OpenAccessLink | https://doaj.org/article/2894193eced541e9ba0244198f550d3f |
| PMID | 34436030 |
| PQID | 2564948729 |
| PQPubID | 23479 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_2894193eced541e9ba0244198f550d3f pubmedcentral_primary_oai_pubmedcentral_nih_gov_8395510 proquest_miscellaneous_2564948729 pubmed_primary_34436030 crossref_primary_10_3390_curroncol28040264 crossref_citationtrail_10_3390_curroncol28040264 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20210809 |
| PublicationDateYYYYMMDD | 2021-08-09 |
| PublicationDate_xml | – month: 8 year: 2021 text: 20210809 day: 9 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Current oncology (Toronto) |
| PublicationTitleAlternate | Curr Oncol |
| PublicationYear | 2021 |
| Publisher | MDPI MDPI AG |
| Publisher_xml | – name: MDPI – name: MDPI AG |
| References | Leis (ref_6) 2012; 31 ref_50 Moul (ref_40) 1996; 120 Williams (ref_45) 1994; 13 Annovazzi (ref_25) 2011; 8 ref_13 ref_55 Assadollahi (ref_3) 2015; 17 ref_53 Ali (ref_2) 2011; 85 Li (ref_52) 2012; 13 Osman (ref_14) 2020; 21 Liu (ref_36) 2019; 98 Lohmann (ref_41) 2000; 42 Chung (ref_48) 2018; 8 Wuebben (ref_33) 2017; 8 Liu (ref_32) 2016; 64 Ma (ref_5) 2007; 132 ref_23 Boumahdi (ref_27) 2014; 511 Rassouli (ref_12) 2014; 30 Conway (ref_34) 2015; 24 Zhou (ref_47) 2011; 278 Wittekind (ref_19) 2006; 27 Zheng (ref_28) 2015; 8 Yu (ref_10) 2016; 44 Walton (ref_43) 1993; 53 Subramaniam (ref_20) 2013; 2 Xia (ref_15) 2021; 6 Chou (ref_42) 2013; 31 Avila (ref_1) 2006; 25 Saigusa (ref_49) 2009; 16 Jung (ref_8) 2014; 16 Liu (ref_16) 2012; 30 ref_35 Chen (ref_29) 2008; 283 Yin (ref_7) 2008; 48 Wang (ref_11) 2009; 29 Novak (ref_57) 2019; 67 Liu (ref_31) 2013; 25 Song (ref_30) 2020; 2020 ref_38 Javaeed (ref_54) 2019; 10 Ding (ref_37) 2020; 9 (ref_18) 2012; 18 Zhang (ref_26) 2013; 2 Guo (ref_17) 2002; 8 Ruiz (ref_24) 2019; 2019 Basati (ref_22) 2020; 51 Garcia (ref_39) 2002; 10 Pereira (ref_21) 2020; 20 Ikeguchi (ref_44) 2002; 95 Hu (ref_58) 2012; 2 ref_9 Sun (ref_4) 2013; 30 Yamashita (ref_56) 2014; 49 Han (ref_51) 2019; 2019 Tomasson (ref_46) 2009; 106 |
| References_xml | – volume: 10 start-page: 210 year: 2002 ident: ref_39 article-title: Hepatocellular carcinoma and markers of apoptosis (bcl-2, bax, bcl-x): Prognostic significance publication-title: Appl. Immunohistochem. Mol. Morphol. doi: 10.1097/00129039-200209000-00004 – volume: 2019 start-page: 3905817 year: 2019 ident: ref_51 article-title: Prognostic value of CD133 and SOX2 in advanced cancer publication-title: J. Oncol. doi: 10.1155/2019/3905817 – ident: ref_35 doi: 10.1371/journal.pone.0065380 – volume: 16 start-page: 470 year: 2014 ident: ref_8 article-title: Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays publication-title: Breast Cancer Res. doi: 10.1186/s13058-014-0470-2 – volume: 25 start-page: 3866 year: 2006 ident: ref_1 article-title: New therapies for hepatocellular carcinoma publication-title: Oncogene doi: 10.1038/sj.onc.1209550 – ident: ref_53 doi: 10.1371/journal.pone.0071140 – volume: 95 start-page: 1938 year: 2002 ident: ref_44 article-title: Quantitative analysis of apoptosis-related gene expression in hepatocellular carcinoma publication-title: Cancer doi: 10.1002/cncr.10898 – volume: 24 start-page: 921 year: 2015 ident: ref_34 article-title: Racial variation in breast tumor promoter methylation in the Carolina Breast Cancer Study publication-title: Cancer Epidemiol. Prev. Biomark. doi: 10.1158/1055-9965.EPI-14-1228 – volume: 2019 start-page: 7683817 year: 2019 ident: ref_24 article-title: Genes Involved in the Transcriptional Regulation of Pluripotency Are Expressed in Malignant Tumors of the Uterine Cervix and Can Induce Tumorigenic Capacity in a Nontumorigenic Cell Line publication-title: Stem Cells Int. doi: 10.1155/2019/7683817 – volume: 18 start-page: 258 year: 2012 ident: ref_18 article-title: Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period publication-title: Clin. Mol. Hepatol. doi: 10.3350/cmh.2012.18.3.258 – volume: 20 start-page: 480 year: 2020 ident: ref_21 article-title: CYP19A1 gene expression in the peripheral blood of Brazilian women with breast cancer relapse publication-title: BMC Cancer doi: 10.1186/s12885-020-06978-z – ident: ref_23 doi: 10.1371/journal.pone.0008960 – volume: 2 start-page: 33 year: 2013 ident: ref_20 article-title: A review of hepatocellular carcinoma (HCC) staging systems publication-title: Chin. Clin. Oncol. – volume: 64 start-page: 814 year: 2016 ident: ref_32 article-title: SIRT1-mediated transcriptional regulation of SOX2 is important for self-renewal of liver cancer stem cells publication-title: Hepatology doi: 10.1002/hep.28690 – volume: 511 start-page: 246 year: 2014 ident: ref_27 article-title: SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma publication-title: Nature doi: 10.1038/nature13305 – volume: 98 start-page: e15414 year: 2019 ident: ref_36 article-title: Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma publication-title: Medicine doi: 10.1097/MD.0000000000015414 – volume: 49 start-page: 1105 year: 2014 ident: ref_56 article-title: Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells publication-title: J. Gastroenterol. doi: 10.1007/s00535-014-0951-1 – volume: 132 start-page: 2542 year: 2007 ident: ref_5 article-title: Identification and characterization of tumorigenic liver cancer stem/progenitor cells publication-title: Gastroenterology doi: 10.1053/j.gastro.2007.04.025 – volume: 51 start-page: 41 year: 2020 ident: ref_22 article-title: Association of high expression levels of SOX2, NANOG, and OCT4 in gastric cancer tumor tissues with progression and poor prognosis publication-title: J. Gastrointest. Cancer doi: 10.1007/s12029-018-00200-x – volume: 13 start-page: 7663 year: 2012 ident: ref_52 article-title: Expression of sox2 and oct4 and their clinical significance in human non-small-cell lung cancer publication-title: Int. J. Mol. Sci. doi: 10.3390/ijms13067663 – volume: 25 start-page: 1264 year: 2013 ident: ref_31 article-title: The multiple roles for Sox2 in stem cell maintenance and tumorigenesis publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2013.02.013 – volume: 30 start-page: 503 year: 2013 ident: ref_4 article-title: Sox2 expression predicts poor survival of hepatocellular carcinoma patients and it promotes liver cancer cell invasion by activating Slug publication-title: Med. Oncol. doi: 10.1007/s12032-013-0503-1 – volume: 85 start-page: 12292 year: 2011 ident: ref_2 article-title: Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts publication-title: J. Virol. doi: 10.1128/JVI.05920-11 – volume: 10 start-page: 234 year: 2019 ident: ref_54 article-title: Metastatic potential and prognostic significance of SOX2: A meta-analysis publication-title: World J. Clin. Oncol. doi: 10.5306/wjco.v10.i6.234 – volume: 67 start-page: 74 year: 2019 ident: ref_57 article-title: SOX2 in development and cancer biology publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.08.007 – volume: 8 start-page: 44917 year: 2017 ident: ref_33 article-title: The dark side of SOX2: Cancer-a comprehensive overview publication-title: Oncotarget doi: 10.18632/oncotarget.16570 – volume: 31 start-page: 2607 year: 2013 ident: ref_42 article-title: The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer publication-title: Stem Cells doi: 10.1002/stem.1518 – volume: 42 start-page: 61 year: 2000 ident: ref_41 article-title: Bcl-2: Bax and Bcl-2: Bcl-x ratios by image cytometric quantitation of immunohistochemical expression in ovarian carcinoma: Correlation with prognosis publication-title: Cytom. Part A doi: 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5 – volume: 17 start-page: e5186 year: 2015 ident: ref_3 article-title: Comparison of Oct4, Sox2 and Nanog Expression in Pancreatic Cancer Cell Lines and Human Pancreatic Tumor publication-title: Zahedan J. Res. Med. Sci. – volume: 16 start-page: 3488 year: 2009 ident: ref_49 article-title: Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy publication-title: Ann. Surg. Oncol. doi: 10.1245/s10434-009-0617-z – volume: 8 start-page: 1059 year: 2002 ident: ref_17 article-title: Effect of bax, bcl-2 and bcl-xL on regulating apoptosis in tissues of normal liver and hepatocellular carcinoma publication-title: World J. Gastroenterol. doi: 10.3748/wjg.v8.i6.1059 – volume: 8 start-page: 139 year: 2011 ident: ref_25 article-title: SOX2 expression and amplification in gliomas and glioma cell lines publication-title: Cancer Genom. Proteom. – volume: 9 start-page: 3057 year: 2020 ident: ref_37 article-title: Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma publication-title: Cancer Med. doi: 10.1002/cam4.2968 – volume: 27 start-page: 289 year: 2006 ident: ref_19 article-title: Pitfalls in der Klassifikation von Lebertumoren publication-title: Der. Pathol. doi: 10.1007/s00292-006-0834-1 – volume: 2 start-page: e61 year: 2013 ident: ref_26 article-title: SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells publication-title: Oncogenesis doi: 10.1038/onc.2012.28 – volume: 13 start-page: 105 year: 1994 ident: ref_45 article-title: Signal transduction pathways involving the Raf proto-oncogene publication-title: Cancer Metastasis Rev. doi: 10.1007/BF00690421 – volume: 21 start-page: 2961 year: 2020 ident: ref_14 article-title: The Clinical and Prognostic Implications of Pluripotent Stem Cell Markers Expression and Their Correlation with the WNT signal pathway in Hepatocellular Carcinoma publication-title: Asian Pac. J. Cancer Prev. doi: 10.31557/APJCP.2020.21.10.2961 – volume: 31 start-page: 1354 year: 2012 ident: ref_6 article-title: Sox2 expression in breast tumours and activation in breast cancer stem cells publication-title: Oncogene doi: 10.1038/onc.2011.338 – volume: 283 start-page: 17969 year: 2008 ident: ref_29 article-title: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer publication-title: J. Biol. Chem. doi: 10.1074/jbc.M802917200 – ident: ref_50 doi: 10.1371/journal.pone.0011022 – volume: 106 start-page: 745 year: 2009 ident: ref_46 article-title: Cancer stem cells: A guide for skeptics publication-title: J. Cell. Biochem. doi: 10.1002/jcb.22050 – volume: 44 start-page: 1818 year: 2016 ident: ref_10 article-title: Expressions of stem cell transcription factors Nanog and Oct4 in renal cell carcinoma tissues and clinical significance publication-title: Artif. Cells Nanomed. Biotechnol. doi: 10.3109/21691401.2015.1105238 – volume: 2020 start-page: 3761535 year: 2020 ident: ref_30 article-title: Clinical and Survival Impact of Sex-Determining Region Y-Box 2 in Colorectal Cancer: An Integrated Analysis of the Immunohistochemical Study and Bioinformatics Analysis publication-title: J. Oncol. doi: 10.1155/2020/3761535 – volume: 278 start-page: 403 year: 2011 ident: ref_47 article-title: Bcl-2 and Bcl-xL play important roles in the crosstalk between autophagy and apoptosis publication-title: FEBS J. doi: 10.1111/j.1742-4658.2010.07965.x – volume: 6 start-page: 1330 year: 2021 ident: ref_15 article-title: Tumor-targeted delivery of siRNA to silence Sox2 gene expression enhances therapeutic response in hepatocellular carcinoma publication-title: Bioact. Mater. – volume: 29 start-page: 1233 year: 2009 ident: ref_11 article-title: Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma publication-title: Anticancer Res. – ident: ref_38 doi: 10.1186/1471-230X-12-118 – ident: ref_9 doi: 10.1186/1471-2407-13-317 – volume: 30 start-page: 1466 year: 2012 ident: ref_16 article-title: The role and significance of Bcl-2 and Bax in the hepatic carcinoma publication-title: Int. J. Morphol doi: 10.4067/S0717-95022012000400032 – volume: 120 start-page: 159 year: 1996 ident: ref_40 article-title: Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancer publication-title: Surgery doi: 10.1016/S0039-6060(96)80283-2 – ident: ref_13 doi: 10.1371/journal.pone.0099594 – volume: 2 start-page: 340 year: 2012 ident: ref_58 article-title: Targeting cancer stem cells: A new therapy to cure cancer patients publication-title: Am. J. Cancer Res. – volume: 30 start-page: e315 year: 2014 ident: ref_12 article-title: SOX2 expression in gastrointestinal cancers of Iranian patients publication-title: Int. J. Biol. Markers doi: 10.5301/jbm.5000137 – volume: 8 start-page: 1677 year: 2018 ident: ref_48 article-title: SOX2 activation predicts prognosis in patients with head and neck squamous cell carcinoma publication-title: Sci. Rep. doi: 10.1038/s41598-018-20086-w – ident: ref_55 doi: 10.1186/s12885-015-2015-1 – volume: 8 start-page: 22382 year: 2015 ident: ref_28 article-title: Clinicopathological significance of Sox2 expression in patients with breast cancer: A meta-analysis publication-title: Int. J. Clin. Exp. Med. – volume: 48 start-page: 1528 year: 2008 ident: ref_7 article-title: Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene publication-title: Hepatology doi: 10.1002/hep.22510 – volume: 53 start-page: 1853 year: 1993 ident: ref_43 article-title: Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis publication-title: Cancer Res. |
| SSID | ssj0033777 |
| Score | 2.3096802 |
| Snippet | Sex-determining region Y-box 2 (SOX2) is a stem cell transcription factor and a major regulator of self-renewal and pluripotency of cancer stem cells (CSCs).... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3015 |
| SubjectTerms | Bax Bcl-2 Biomarkers, Tumor - genetics cancer stem cell Carcinoma, Hepatocellular - diagnosis Carcinoma, Hepatocellular - genetics hepatocellular carcinoma Humans Liver Neoplasms - genetics Neoplasm Recurrence, Local Prognosis Proto-Oncogene Proteins c-bcl-2 SOXB1 Transcription Factors - genetics SRY-box 2 (SOX2) |
| Title | SOX2 and Bcl-2 as a Novel Prognostic Value in Hepatocellular Carcinoma Progression |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34436030 https://www.proquest.com/docview/2564948729 https://pubmed.ncbi.nlm.nih.gov/PMC8395510 https://doaj.org/article/2894193eced541e9ba0244198f550d3f |
| Volume | 28 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Na9wwEBUhh5JL6Ufauk2CCjkVTGRJluxjEhKWQtKQNmVvRp80sJXLZre_PzOWd8mmob30ZiwJi5mx9MZ6fkPIYV03TNvK46muK6WOqmxUa8vYRBVEbdpmqEVwcakmN_LztJ4-KPWFnLAsD5wNdwQJgQSQEVzwtaxCaw3sKnCniYCtvYi4-rKWrZKpvAYLoXUuq4I_kLGa5_NMAQn-kVvO530CK_MGApgrubEjDcL9T6HNx6TJB7vQ-QvyfISP9DhP-yXZCukVeXYxHpC_Jtdfv0w5NcnTEzcr4eqOGnrZ_w4zejXvkVQHA-l3M1sGepvoBDajRY8f75GNSk-xsFDqf5qhc2bIpl1yc3727XRSjmUTSidVvSiVc5DxWq-MboTVkVnPQ-ShjS5G7YVgLQf3RG5lpasWWrkyQrtopPeQ7ok3ZDv1Kbwj1IiorbFaeVlJi0xVwCcoyM6EcdBUELYyXedGTXEsbTHrILdAa3d_WLsgn9ZDfmVBjb91PkF_rDuiFvZwAyKkGyOk-1eEFOTjypsdvDtoU5NCv7zrAO6hOg7kFwV5m727fpSQUihYAQuiN_y-MZfNlnT7Y9DnBswJOJS9_x-T_0B2OLJoBpLKHtlezJdhH2DQwh4MEX8P47EEng |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SOX2+and+Bcl-2+as+a+Novel+Prognostic+Value+in+Hepatocellular+Carcinoma+Progression&rft.jtitle=Current+oncology+%28Toronto%29&rft.au=Hosseini-Khah%2C+Zahra&rft.au=Babaei%2C+Mohammad+Reza&rft.au=Tehrani%2C+Mohsen&rft.au=Cucchiarini%2C+Magali&rft.date=2021-08-09&rft.issn=1718-7729&rft.eissn=1718-7729&rft.volume=28&rft.issue=4&rft.spage=3015&rft_id=info:doi/10.3390%2Fcurroncol28040264&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1718-7729&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1718-7729&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1718-7729&client=summon |